Alector (ALEC) Projected to Post Earnings on Wednesday

Alector (NASDAQ:ALEC) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Alector to post earnings of ($0.39) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Alector Stock Up 5.3%

Alector stock opened at $1.97 on Wednesday. The stock has a market capitalization of $215.03 million, a PE ratio of -1.84 and a beta of 0.64. The business has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $2.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.76 and a quick ratio of 3.76. Alector has a 12 month low of $0.87 and a 12 month high of $3.40.

Analyst Ratings Changes

ALEC has been the subject of a number of research reports. HC Wainwright cut their target price on shares of Alector from $10.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research report on Wednesday, January 21st. BTIG Research upgraded shares of Alector from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Cantor Fitzgerald cut Alector from an “overweight” rating to a “neutral” rating in a report on Wednesday, October 22nd. Finally, Mizuho set a $1.50 target price on Alector and gave the stock a “neutral” rating in a research note on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.25.

Insider Transactions at Alector

In other Alector news, CFO Neil Lindsay Berkley sold 37,261 shares of Alector stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $41,732.32. Following the sale, the chief financial officer owned 374,309 shares of the company’s stock, valued at approximately $419,226.08. The trade was a 9.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Arnon Rosenthal sold 104,347 shares of Alector stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $116,868.64. Following the completion of the sale, the chief executive officer owned 2,420,040 shares in the company, valued at approximately $2,710,444.80. This trade represents a 4.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 196,104 shares of company stock worth $220,064 over the last 90 days. 9.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alector

Several institutional investors have recently modified their holdings of ALEC. Jane Street Group LLC boosted its position in shares of Alector by 4.7% in the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock worth $316,000 after buying an additional 11,618 shares in the last quarter. Strs Ohio acquired a new position in shares of Alector in the 1st quarter valued at about $126,000. Geode Capital Management LLC boosted its position in Alector by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,982,068 shares of the company’s stock worth $2,775,000 after purchasing an additional 19,970 shares during the period. Prudential Financial Inc. purchased a new position in Alector in the 2nd quarter worth approximately $30,000. Finally, XTX Topco Ltd boosted its position in Alector by 125.2% in the 2nd quarter. XTX Topco Ltd now owns 73,338 shares of the company’s stock valued at $103,000 after buying an additional 40,767 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.